Skip to main content

REVIEW Structural Insights Into AGC Kinase Inhibition

Buy Article:

$45.00 plus tax (Refund Policy)

The AGC group of protein kinases comprises several targets for small molecule inhibitors of therapeutic significance. Crystal structure data facilitate the design or improvement of selective inhibitory molecules. Cross-selectivity of kinase inhibitors is often observed among closely related enzymes. Usually an obstacle for inhibitor design, cross-selectivity can be useful to obtain structural data from a related kinase, if not available from the original target. Protein kinase A (PKA), a representative of the AGC kinase group, has been cocrystallized with AGC group inhibitors from diverse chemical groups, thus providing structural information about binding modes, selectivity, and cross-selectivity. “Ersatz” kinases were created by mutating the inhibitor binding site of PKA to resemble other related kinases from the AGC group. The cocrystallization of these ersatz kinases with certain AGC group small molecule inhibitors elucidated some aspects of protein kinase inhibitor selectivity in this group of kinases.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cancer; Crystal structure; Inhibitor selectivity; Mutagenesis; Protein kinase C inhibitor; Rho-kinase inhibitor; Surrogate kinase

Document Type: Review Article

Affiliations: 1: *Abteilung Strukturforschung, Max-Planck-Institut fuer Biochemie, D-82152 Martinsried, Germany 2: †Department for Pathochemistry, German Cancer Research Centre, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany

Publication date: 01 January 2003

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more